Veeva (VEEV) Q2 2027 Earnings Call Transcript
Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest near‑term upside, while the sizable repurchase adds support. Execution risk remains around new product rollouts.
Market read
Strong earnings and guidance lift Veeva and may positively affect the broader life‑sciences SaaS sector.
What to watch
Potential integration risk of the Falcon platform and execution risk in expanding the Aspen horizontal CRM.
Background
Veeva Systems reported Q2 2027 results, highlighting subscription revenue growth, new AI‑driven Falcon platform, and a $81.8M acquisition.
Ticker impact
Q2 2027 earnings release with revenue of $928M, 18% YoY growth, raised FY2027 revenue guidance to $3.682‑$3.687B and announced $472.7M stock repurchase.
Potential short‑term rally, especially in the life‑sciences software sector.
Guidance lift and sizable buyback are fresh, material facts that can move the stock immediately.
Market effects
Signals continued strength in cloud‑based life‑sciences SaaS, may boost peers like IQV and other CRM providers.
Highlights growth in U.S. and China life‑sciences markets, could influence regional biotech funding.
Reinforces demand for AI‑driven enterprise software globally.
Counterpoint
If guidance misses consensus expectations, the stock could face a pull‑back despite buyback.
Key entities
- CEOPeter Gassner
Provided commentary on AI and Falcon platform.
- CFOBrian Van Wagener
Discussed financial results and guidance.
